Cognito Therapeutics has raised $105 million to support its Alzheimer's treatment device, Spectris, which uses gamma frequency light and sound to restore brain activity; the company is awaiting pivotal trial data and plans to seek FDA clearance this year.
Cognito Therapeutics' recent $105 million funding round, led by prominent investors like Morningside Ventures and IAG Capital Partners, emphasizes the growing investment interest in neurodegenerative treatment devices. As they await pivotal trial data for their Alzheimer's treatment device, Spectris, this could signal a significant opportunity for stakeholders in healthtech and biotech, especially those focused on FDA approval processes and the commercialization of innovative medical devices.